Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 13,117,200 | 12,172,900 | 16,071,700 | 8,497,100 | 6,557,600 |
| Cost of Goods | 1,815,800 | 1,560,400 | 2,437,500 | 1,119,900 | 765,100 |
| Gross Profit | 11,301,400 | 10,612,500 | 13,634,200 | 7,377,200 | 5,792,500 |
| Operating Expenses | 7,255,101 | 5,874,000 | 4,687,900 | 3,801,500 | 3,582,800 |
| Operating Income | 4,047,100 | 4,738,900 | 8,946,800 | 3,576,600 | 2,209,800 |
| Interest Expense | 73,000 | 59,400 | 57,300 | 56,900 | 30,200 |
| Other Income | 225,200 | 179,300 | 436,300 | 290,700 | 249,500 |
| Pre-tax Income | 4,199,300 | 4,858,800 | 9,325,800 | 3,810,400 | 2,429,100 |
| Income Tax | 245,700 | 520,400 | 1,250,500 | 297,200 | 313,300 |
| Net Income Continuous | 3,953,600 | 4,338,400 | 8,075,300 | 3,513,200 | 2,115,800 |
| Net Income | $3,953,600 | $4,338,400 | $8,075,300 | $3,513,200 | $2,115,800 |
| EPS Basic Total Ops | 37.05 | 40.51 | 76.40 | 32.65 | 19.38 |
| EPS Basic Continuous Ops | 37.05 | 40.51 | 76.40 | 32.65 | 19.38 |
| EPS Diluted Total Ops | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 |
| EPS Diluted Continuous Ops | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 |
| EPS Diluted Before Non-Recurring Items | 37.66 | 40.11 | 74.66 | 28.66 | 21.47 |
| EBITDA(a) | $4,468,100 | $5,080,300 | $9,233,001 | $3,812,500 | $2,420,100 |